Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit

Thomas L. Klitgaard*, Olav L. Schjørring, Frederik M. Nielsen, Christian S. Meyhoff, Anders Perner, Jørn Wetterslev, Bodil S. Rasmussen, Marija Barbateskovic

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

15 Citationer (Scopus)

Abstract

Background: This is an updated review concerning 'Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit'. Supplementary oxygen is provided to most patients in intensive care units (ICUs) to prevent global and organ hypoxia (inadequate oxygen levels). Oxygen has been administered liberally, resulting in high proportions of patients with hyperoxemia (exposure of tissues to abnormally high concentrations of oxygen). This has been associated with increased mortality and morbidity in some settings, but not in others. Thus far, only limited data have been available to inform clinical practice guidelines, and the optimum oxygenation target for ICU patients is uncertain. Because of the publication of new trial evidence, we have updated this review. Objectives: To update the assessment of benefits and harms of higher versus lower fractions of inspired oxygen (FiO2) or targets of arterial oxygenation for adults admitted to the ICU. Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, BIOSIS Previews, and LILACS. We searched for ongoing or unpublished trials in clinical trial registers and scanned the reference lists and citations of included trials. Literature searches for this updated review were conducted in November 2022. Selection criteria: We included randomised controlled trials (RCTs) that compared higher versus lower FiO2 or targets of arterial oxygenation (partial pressure of oxygen (PaO2), peripheral or arterial oxygen saturation (SpO2 or SaO2)) for adults admitted to the ICU. We included trials irrespective of publication type, publication status, and language. We excluded trials randomising participants to hypoxaemia (FiO2 below 0.21, SaO2/SpO2 below 80%, or PaO2 below 6 kPa) or to hyperbaric oxygen, and cross-over trials and quasi-randomised trials. Data collection and analysis: Four review authors independently, and in pairs, screened the references identified in the literature searches and extracted the data. Our primary outcomes were all-cause mortality, the proportion of participants with one or more serious adverse events (SAEs), and quality of life. We analysed all outcomes at maximum follow-up. Only three trials reported the proportion of participants with one or more SAEs as a composite outcome. However, most trials reported on events categorised as SAEs according to the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) criteria. We, therefore, conducted two analyses of the effect of higher versus lower oxygenation strategies using 1) the single SAE with the highest reported proportion in each trial, and 2) the cumulated proportion of participants with an SAE in each trial. Two trials reported on quality of life. Secondary outcomes were lung injury, myocardial infarction, stroke, and sepsis. No trial reported on lung injury as a composite outcome, but four trials reported on the occurrence of acute respiratory distress syndrome (ARDS) and five on pneumonia. We, therefore, conducted two analyses of the effect of higher versus lower oxygenation strategies using 1) the single lung injury event with the highest reported proportion in each trial, and 2) the cumulated proportion of participants with ARDS or pneumonia in each trial. We assessed the risk of systematic errors by evaluating the risk of bias in the included trials using the Risk of Bias 2 tool. We used the GRADEpro tool to assess the overall certainty of the evidence. We also evaluated the risk of publication bias for outcomes reported by 10b or more trials. Main results: We included 19 RCTs (10,385 participants), of which 17 reported relevant outcomes for this review (10,248 participants). For all-cause mortality, 10 trials were judged to be at overall low risk of bias, and six at overall high risk of bias. For the reported SAEs, 10 trials were judged to be at overall low risk of bias, and seven at overall high risk of bias. Two trials reported on quality of life, of which one was judged to be at overall low risk of bias and one at high risk of bias for this outcome. Meta-analysis of all trials, regardless of risk of bias, indicated no significant difference from higher or lower oxygenation strategies at maximum follow-up with regard to mortality (risk ratio (RR) 1.01, 95% confidence interval (C)I 0.96 to 1.06; I2 = 14%; 16 trials; 9408 participants; very low-certainty evidence); occurrence of SAEs: the highest proportion of any specific SAE in each trial RR 1.01 (95% CI 0.96 to 1.06; I2 = 36%; 9466 participants; 17 trials; very low-certainty evidence), or quality of life (mean difference (MD) 0.5 points in participants assigned to higher oxygenation strategies (95% CI -2.75 to 1.75; I2 = 34%, 1649 participants; 2 trials; very low-certainty evidence)). Meta-analysis of the cumulated number of SAEs suggested benefit of a lower oxygenation strategy (RR 1.04 (95% CI 1.02 to 1.07; I2 = 74%; 9489 participants; 17 trials; very low certainty evidence)). However, trial sequential analyses, with correction for sparse data and repetitive testing, could reject a relative risk increase or reduction of 10% for mortality and the highest proportion of SAEs, and 20% for both the cumulated number of SAEs and quality of life. Given the very low-certainty of evidence, it is necessary to interpret these findings with caution. Meta-analysis of all trials indicated no statistically significant evidence of a difference between higher or lower oxygenation strategies on the occurrence of lung injuries at maximum follow-up (the highest reported proportion of lung injury RR 1.08, 95% CI 0.85 to 1.38; I2 = 0%; 2048 participants; 8 trials; very low-certainty evidence). Meta-analysis of all trials indicated harm from higher oxygenation strategies as compared with lower on the occurrence of sepsis at maximum follow-up (RR 1.85, 95% CI 1.17 to 2.93; I2 = 0%; 752 participants; 3 trials; very low-certainty evidence). Meta-analysis indicated no differences regarding the occurrences of myocardial infarction or stroke. Authors' conclusions: In adult ICU patients, it is still not possible to draw clear conclusions about the effects of higher versus lower oxygenation strategies on all-cause mortality, SAEs, quality of life, lung injuries, myocardial infarction, stroke, and sepsis at maximum follow-up. This is due to low or very low-certainty evidence.

OriginalsprogEngelsk
ArtikelnummerCD012631
TidsskriftCochrane Database of Systematic Reviews
Vol/bind2023
Udgave nummer9
Antal sider198
ISSN1465-1858
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The trial was funded by public grants.

Funding Information:
The trial was funded by public grants (the French Ministry of Health).

Funding Information:
Fourteen trials were funded by public grants (Asfar 2017; Barrot 2020; Gelissen 2021; Girardis 2016; Gomersall 2002; Lång 2018; Mackle 2020; Martin 2021; Mazdeh 2015; Panwar 2016; Taher 2016; Schmidt 2022; Yang 2019; Yang 2021); two trials did not report how they were funded (Ishii 2018; Jun 2019); two trials were funded by public and private grants, and specified that funding bodies had no input regarding the design, management, or reporting of the trial (Jakkula 2018; Schjørring 2021). One trial was funded by public grants and specified that funding bodies had no input regarding the design, management, or reporting of the trial (Semler 2022).

Funding Information:
The trial was funded by public and private funds; the funding bodies had no input regarding the design, management, or reporting of the trial.

Funding Information:
Fourteen trials were funded by public grants (Asfar 2017; Barrot 2020; Gelissen 2021; Girardis 2016; Gomersall 2002; Lång 2018; Mackle 2020; Martin 2021; Mazdeh 2015; Panwar 2016; Taher 2016; Schmidt 2022; Yang 2019; Yang 2021); two trials did not report how they were funded (Ishii 2018; Jun 2019); two trials were funded by public and private grants, and specified that funding bodies had no input regarding the design, management, or reporting of the trial (Jakkula 2018; Schjørring 2021). One trial was funded by public grants and specified that funding bodies had no input regarding the design, management, or reporting of the trial (Semler 2022). We would like to thank Harald Herkner (EC Signoff Editor), Sharon Einav (Handling Editor), Vernon Paul Hedge and Naomi Dayan (Managing Editors), Heather Maxwell and Maggie Hellwig (Copy-editors), Janne Vendt and Anne-Marie Klint Jørgensen (Information Specialists), Cathal Walsh (Statistical Editor), Andrew Cumpstey (Peer Reviewers), and Janet Wale (Consumer Referee) for their help and editorial advice during the preparation of this updated systematic review.

Publisher Copyright:
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Citationsformater